ClinicalTrials.gg
Not yet recruitingNCT06856772STATIN-C3Updated Mar 4, 2025

Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) Trial

A Phase 4 interventional study of Statin in the evening (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin) and Statin in the morning (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin) in Cardiovascular Diseases (CVD), Drug Effect and Atherosclerosis Cardiovascular Disease, sponsored by Tor Biering-Sørensen. Not yet recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-04.

Sponsored by Tor Biering-Sørensen · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
42,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Statins inhibit hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase which catalyzes the rate-limiting step in cholesterol synthesis. This in turn leads to reductions in concentrations of low-density lipoprotein (LDL) cholesterol and C-reactive protein which reduces the risk of incident atherosclerotic events among individuals both with and without a history of atherosclerotic cardiovascular Several pilot studies have suggested potential benefits of taking statin in the evening rather than in the morning.

The primary objective of this study is to examine whether statin administration at bedtime versus in the morning provides a superior reduction in the incidence of major adverse cardiovascular events among patients with or without established atherosclerotic cardiovascular disease, who are already taking statin.

Read the detailed description

The study is a pragmatic, registry-based, open-label, randomized controlled trial combining the utilization of the Danish nationwide health registries and the official Danish electronic letter system (Digital Post/eBoks) into an innovative, decentralized trial requiring no study visits from participants. The nationwide health registries will be used for identification of potential participants and data collection, including baseline information and follow-up data, while the electronic letter system will be used for sending recruitment letters and communicating with participants. Study participants will provide electronic informed consent from home before inclusion and randomization.

The trial will include patients currently in statin treatment regardless of the presence or absence of established cardiovascular disease. Participants will be randomized 1:1 to either statin administration at bedtime or in the morning. The trial is event-driven.

02

Conditions studied

  • Cardiovascular Diseases (CVD)
  • Drug Effect
  • Atherosclerosis Cardiovascular Disease

Keywords

  • Statin
  • Circadian Rhythm
  • Randomized Controlled Trial
  • Pragmatic
  • Outcomes
  • Cardiovascular disease
  • Prevention
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 42,000 is above the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Tor Biering-Sørensen is the lead sponsor of 22 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >=18 years
  • Current treatment with atorvastatin 10-80 mg, rosuvastatin 5-40 mg, simvastatin 10-80 mg or pravastatin 20-40 mg (as recorded in the Danish National Prescription Registry and confirmed by the participant via questionnaire)
  • Signed

Exclusion criteria

Exclusion Criteria:

  • none
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42,000 participants (estimated)

Study arms

  • Experimental
    Statin at bedtime

    Statin in the current prescribed dose

    Drug: Statin in the evening (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)

  • Experimental
    Statin in the morning

    Statin in the current prescribed dose

    Drug: Statin in the morning (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)

Interventions

  • DrugStatin in the evening (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)

    Participants will be instructed to take their Statin daily at approx. 8PM-12AM.

  • DrugStatin in the morning (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)

    Participants will be instructed to take their statin upon awakening/or with their breakfast (approx. 6AM-10AM).

06

What researchers measure

Primary outcomes

  1. Composite of hospitalization for myocardial infarction, hospitalization for stroke or cardiovascular death

    For Hospitalizations: Inpatient, at least 1 night

    Time frame: Will be assessed in a time-to-first-event approach from date of randomization until end of study (up til 5 years).

Secondary outcomes

  1. Hospitalization for myocardial infarction

    Inpatient, at least 1 night

    Time frame: Will be assessed in a time-to-first-event approach from date of randomization until end of study (up til 5 years).

  2. Hospitalization for stroke

    Inpatient, at least 1 night

    Time frame: Will be assessed in a time-to-first-event approach from date of randomization until end of study (up til 5 years).

  3. Cardiovascular death

    Time frame: Will be assessed in a time-to-first-event approach from date of randomization until end of study (up til 5 years).

  4. All-cause death

    Time frame: Will be assessed in a time-to-first-event approach from date of randomization until end of study (up til 5 years).

Other outcomes

  1. Hospitalization for unstable angina

    Inpatient, at least 1 night

    Time frame: Will be assessed in a time-to-first-event approach from date of randomization until end of study (up til 5 years).

  2. Coronary revascularization

    Time frame: Will be assessed in a time-to-first-event approach from date of randomization until end of study (up til 5 years).

  3. Any arterial revascularization

    Time frame: Will be assessed in a time-to-first-event approach from date of randomization until end of study (up til 5 years).

  4. Any venous thromboembolism

    The incidence of Any venous thromboembolism

    Time frame: Will be assessed in a time-to-first-event approach from date of randomization until end of study (up til 5 years).

  5. Hospitalization for heart failure

    The incidence of Hospitalization for heartfailure. For hospitalizations: Inpatient, at least 1 night

    Time frame: Will be assessed in a time-to-first-event approach from date of randomization until end of study (up til 5 years).

  6. Hospitalization for rhabdomyolysis

    The incidence of Hospitalization for rhabdomyolysis, Inpatient, at least 1 night.

    Time frame: From date of randomization until end of study (up til 5 years)

  7. Any incident cancer

    The incidence of any cancer

    Time frame: From date of randomization until end of study (up til 5 years)

  8. Any incident renal disorder

    The incidence of any renal disorder

    Time frame: From date of randomization until end of study (up til 5 years)

  9. Any incident hepatic disorder

    The incidence of any hepatic disorder

    Time frame: From date of randomization until end of study (up til 5 years)

  10. Bleeding episodes requiring hospitalization

    The incidence of any bleeding episodes requiring hospitalization. For hospitalizations: Inpatient, at least 1 night.

    Time frame: From date of randomization until end of study (up til 5 years)

  11. Any Incident Diabetes mellitus

    The incidence of diabetes mellitus

    Time frame: From date of randomization until end of study (up til 5 years)

  12. Plasma Lipid levels

    Time frame: From date of randomization until end of study (up til 5 years)

  13. Plasma C-reactive protein level

    Time frame: From date of randomization until end of study (up til 5 years)

  14. Time of day of hospitalization for myocardial infarction

    The time of hospitalization will be expressed as the hour of the beginning of the hospitalization

    Time frame: From date of randomization until end of study (up til 5 years)

  15. Time of day of hospitalization for stroke

    The time of hospitalization will expressed as the hour of the beginning of the hospitalization.

    Time frame: From date of randomization until end of study (up til 5 years)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Baseline and endpoint data will be collected from Danish administrative health registries, which are subject to Danish legislation and can only be made available to a third party under certain conditions. Please contact the sponsor in case of any inquiries.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Mar 2028, 37 months later.

Of 107 non-industry phase 4 interventional studies under Cardiovascular Diseases, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 76. This study's planned 37 months is below that.

Counting every sponsor, half of 113 studies reached it within 46 months; a quarter within 26 and three quarters within 64.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Mar 4, 2025
StartEst.
Feb 28, 2025
Primary completionEst.
Mar 28, 2028
CompletionEst.
Mar 28, 2028
Last update
Mar 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06856772
Lead sponsor
Tor Biering-Sørensen
Collaborators
Herlev and Gentofte Hospital
Responsible party
Tor Biering-Sørensen (MD, PhD, MPH, Herlev and Gentofte Hospital) — Sponsor-investigator
First posted
Mar 4, 2025
Start date
Feb 28, 2025 (estimated)
Primary completion
Mar 28, 2028 (estimated)
Completion
Mar 28, 2028 (estimated)
Last update
Mar 4, 2025

Study contacts

Manan Pareek, MD and PhD
Contact
mananpareek@dadlnet.dk
+4525536900

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion